PROMISE TO MAP | Omada's approach to build safety and security into AI-powered products
PROMISE TO MAP is Omada's approach to build safety and security into AI-powered products.
Read Resource
Latest Content
Roundup of most recently released content and assets.
-
-
Omada Health GLP-1 Care Track
Learn More -
Omada Health Reports Second Quarter 2025 Results
Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the second quarter ended June 30, 2025.
Read Article
-
Meet Heather
Meet Heather, a real Omada member from Atlanta, GA in the Omada for Prevention & Weight Health program with the embedded GLP-1 enhanced care track. Here's her journey.
Watch Video
-
Meet Niki
Niki got personalized support and accountability from her coach to make small changes to build lasting healthy habits. Here's her journey.
Watch Video
-
Meet Stephanie
She has multiple chronic conditions and was able to get support from her entire care team to make healthy changes. Here's her journey.
Watch Video
-
Meet Christina
Christina not only got support to make small changes to build healthy habits but with the support Christina got between visits, she was able to lower her medication dosage. Here’s her journey.
Watch Video
-
Patients, providers and payers alike are investing in GLP-1 medications - but are they seeing the value they expected?
In this ~2-minute video, Omada's Senior Director of Clinical and Translational Research, Sarah Linke, summarizes findings of our July 2025 clinical white paper on GLP-1 Persistence
Read Article
-
Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.
Read Article
-
Omada Health’s Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
-
GLP-1 Medication Persistence, a Key Component of Weight Loss
Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Read Resource
-
Omada Health Announces Pricing of Initial Public Offering
Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe
Read Article
-
Omada Health Announces Launch of Initial Public Offering
Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”
Read Article
-
Omada Horizon Day - The Food Experience 2025
On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!
Watch Video
-
3 Reasons Behavior Change Support is Vital to Obesity Care
Why GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.
Read Article
-
5 Key Lessons Learned in the U.S. about Weight Loss Drugs
This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.
Read Article
-
Building Self Efficacy in the Era of GLP-1s
Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.
Read Article
-
Omada Health GLP-1 Care Track
Learn More -
Lower Acute Healthcare Utilization Associated with Virtual Cardiometabolic Health Programs
This analysis found that lifestyle-focused virtual health program to support cardiometabolic disease management may lead to meaningful reductions in high-cost acute care encounters.
Read Article
-
Life After GLP-1s: A Real-World Population Snapshot
This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.
Read Article
-
New Indications, Promising Outcomes, and Third-Party Prescribing
As the GLP-1 conversation evolves, Omada Health is updating its industry FAQs to deliver timely data and insights for virtual care buyers.
Read Article
-
Why Honesty is the Best Policy as AI Continues Shaping Healthcare: Q&A with Lucia Savage, Chief Privacy & Regulatory Officer
Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.
Read Article
-
Loading More...
